Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

HIV Infections Clinical Trial

Official title:

Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01852942
• Other study ID #: 1111M06585
• Secondary ID: 13-3613U01AI1058
• Status: Completed
• Phase: Phase 2
• Start date: September 2014
• Est. completion date: July 16, 2019

Study information

• Verified date: November 2020
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed to test the hypothesis that treatment of HIV infected subjects with losartan, an agent with specific anti-inflammatory and anti-fibrotic actions, will: 1. reverse existing lymphoid tissue fibrosis, 2. restore lymphoid tissue architecture, 3. increase the number and improve the function of peripheral and lymphatic CD4 T cells, 4. decrease levels of systemic immune activation (IA), 5. decrease size of the HIV reservoir, and 6. be safe and well tolerated.

Description:

This is a randomized, double-blind, placebo-controlled trial of 50 HIV-1 infected individuals on stable ART randomized in a 1:1 ratio to losartan (50 mg orally daily titrated to 100 mg daily) vs placebo for 30 months. We plan to enroll a total of 63 HIV infected subjects to ensure that 50 complete the protocol. All HIV infected subjects will undergo biopsies of inguinal lymph node (LN) and gut associated lymphatic tissue (GALT) for primary endpoint analysis at baseline, 12 and 30 months after study enrollment. Blood will be collected at least quarterly throughout the study and an intensive blood pharmacokinetic (PK) study will be conducted at month 1. All HIV infected subjects will be vaccinated with the quadrivalent human papillomavirus (HPV) vaccine at months 23, 25 and 29.5 to measure immune function. 5 HIV uninfected control subjects will also be enrolled. The primary endpoint is to determine the impact of losartan on lymphoid tissue fibrosis in HIV infected, ART treated adults. This will be determined by measuring the amount of collagen deposition in lymphoid tissues and the integrity of the FRCn using immunohistochemistry (IHC) and quantitative image analysis (QIA).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: July 16, 2019
• Est. primary completion date: July 16, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

HIV infected participants:

1. Inclusion Criteria:

Participants must meet all of the following inclusion criteria to participate in this

study:

• HIV-1 infected. -= 18 years of age.
• Baseline peripheral CD4+ T cell count 200-600 cells/mm3 for at least two measures over the 6 months prior to study enrollment. -= 12 months of stable ART, defined as use of a given drug regimen without disruption lasting = 1 week in the period leading up to study enrollment.
• HIV viral load (VL) < 50 copies/mL for at least two consecutive measures over the 6 months prior to study enrollment.
• No contraindication to proposed study procedures.
• Women of child-bearing potential must be willing to use a form of effective contraception for the duration of the study. Effective contraception includes hormonal injection, implant or oral medication, IUD, diaphragm, or cervical cap with spermicide. Condoms cannot be used as the sole form of contraception.

2. Exclusion Criteria: Participants meeting any of the following exclusion criteria at

baseline will be excluded from study participation:

• Use of any immunomodulator within the 12 months prior to study enrollment. An immunomodulator for the purposes of this study is defined as a drug known to either diminish or augment a patient's immune system. Examples of these include, but are not limited to, systemic corticosteroids (use of topical steroids will be permitted), TNF-inhibitors, rituximab, cyclophosphamide, abatacept,cyclosporine, azathioprine, 6-mercaptopurine, methotrexate, sulfasalazine, cyclosporine, tacrolimus,sirolimus, and intravenous immune globulin.
• Current use of an ARB or ACEi.
• Current use of rifaximin, fluconazole or lithium given potential for drug interactions with losartan.
• Prior reaction or intolerance to an ARB or ACEi.
• Prior diagnosis of a chronic inflammatory disease with serologic or clinical evidence as diagnosed by a primary care physician or specialist. Examples of these include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, scleroderma, Sjogren's syndrome, mixed connective tissue disease, psoriasis, polymyositis, dermatomyositis, vasculitis, sarcoidosis, Wegener's granulomatosis, giant cell arteritis, polyarteritis nodosa, gastrointestinal pemphigoid, eosinophilic colitis, Crohn's disease, ulcerative colitis, autoimmune hepatitis, and hepatitis C.
• Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as diagnosed by a primary care physician or specialist (Marfan's syndrome, Ehlers-Danlos syndrome).
• Baseline blood pressure < 110/70.
• Estimated Glomerular Filtration Rate (eGFR) of < 30ml/min/1.73 m2 within 4 weeks of study initiation or history of advanced renal disease.
• AST and/or ALT > 3 times the upper limit of normal within 4 weeks of study enrollment.
• Potassium > 5.0 within 4 weeks of study enrollment.
• Pregnancy.
• In women of childbearing age, unwillingness to use birth control for the duration of the study.
• Breast feeding.
• Prior vaccination with an HPV vaccine, including Cervarix (GlaxoSmithKline) or Gardasil (Merck).
• History of hypersensitivity or severe allergic reactions to yeast.

HIV-uninfected:

1. Inclusion Criteria Participants must meet all of the following inclusion criteria to participate in this

study:

• HIV uninfected. -= 18 years of age.
• No contraindication to proposed study procedures.

2. Exclusion Criteria: Participants meeting any of the following exclusion criteria at

baseline will be excluded from study participation:

• Use of any immunomodulator within the 12 months prior to study enrollment (as defined above).
• Current use of an ARB or ACEi.
• Prior diagnosis of a chronic inflammatory disease with serologic or clinical evidence (as defined above).
• Prior diagnosis of a connective tissue disease with genetic, serologic or clinical evidence as diagnosed by a primary care physician or specialist (Marfan's syndrome, Ehlers-Danlos syndrome).
• Pregnancy.

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• Communicable Diseases
• Fibrosis
• HIV Infection
• HIV Infections
• Infection

Intervention

Drug:
• Losartan
Participants will start with 50 mg of losartan by mouth daily. The dose will be increased to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
• Placebo
one tablet by mouth daily

Locations

Country	Name	City	State
United States	University of Minnesota, Division of Infectious Diseases	Minneapolis	Minnesota

Sponsors (3)

Lead Sponsor	Collaborator
University of Minnesota	Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Frequency of Dendritic Cell and CD4 T Cell Interactions With the FRCn	As an exploratory endpoint, we will determine the impact of losartan on frequency of dendritic cell and CD4 T cell interactions with the FRCn. This will be determined using two-photon microscopy in sections on LN obtained from study subjects. Given that this is an exploratory endpoint, these assays will be performed in a subset of subjects (5 losartan treated, 2 placebo treated and 5 HIV uninfected controls).	30 months
Primary	Collagen Deposition in LT	The Impact of Losartan Treatment on Lymphoid Tissue (LT) Fibrosis will be determined by measuring the amount of collagen deposition in LT using immunohistochemistry (IHC) and quantitative image analysis (QIA). LT will be obtained at baseline, month 12 and month 30.	30 months
Primary	Integrity of the Fibroblastic Reticular Cell Network (FRCn)	The Impact of Losartan Treatment on Lymphoid Tissue (LT) Fibrosis will be determined by measuring the Integrity of the fibroblastic reticular cell network (FRCn) using immunohistochemistry (IHC) and quantitative image analysis (QIA). LT will be obtained at baseline, month 12 and month 30.	30 months
Secondary	Frequency of CD4+ T Cells	Impact of losartan on immune reconstitution and function will be determined by frequency of CD4+ T cells in LT using IHC.	30 months
Secondary	Frequency TUNEL+CD3+CD8+ T Cells	Impact of losartan on immune reconstitution and function will be determined by frequency of TUNEL+CD3+CD8+ T cells in LT using IHC.	30 months
Secondary	Frequency of Cells Expressing TGF-beta and Lymphotoxin-beta	Impact of losartan on immune reconstitution and function will be determined by frequency of cells expressing TGF-beta and lymphotoxin-beta in LT using IHC.	30 months
Secondary	Serum Concentration of IL-7	Impact of losartan on immune reconstitution and function will be determine by serum concentrations of IL-7 measured with ELISA.	30 months
Secondary	Serum Concentration of TGF-beta	Impact of losartan on immune reconstitution and function will be determine by serum concentrations of TGF-beta measured with ELISA.	30 months
Secondary	Immune Response to HPV Vaccination	Impact of losartan on immune reconstitution and function will be determine by measuring the immune response to HPV vaccination using flow cytometry to identify cells stimulated by specific HPV peptides.	30 months
Secondary	Frequency of Activated T-cell Populations - Immunofluorescent Staining	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the frequency of activated T-cell populations (specifically CD3+CD4+CD38+, CD3+,CD8+CD38+,CD4+Ki67+ and CD8+Ki67+ T cells) in LT using immunofluorescence staining	30 months
Secondary	Percent of Activated T Cells in PBMCs - Flow Cytometry	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated T cells in peripheral blood mononuclear cells (PBMCs) using flow cytometry.	30 months
Secondary	Percent of Activated Macrophages in PBMCs - Flow Cytometry	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated macrophages in peripheral blood mononuclear cells (PBMCs) using flow cytometry.	30 months
Secondary	Percent of Activated Dendritic Cells in PBMCs - Flow Cytometry	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated dendritic cells in peripheral blood mononuclear cells (PBMCs) using flow cytometry.	30 months
Secondary	Percent of Activated T Cells in LT - Flow Cytometry	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated T cells in lymphoid tissues (LT) using flow cytometry.	30 months
Secondary	Percent of Activated Macrophages in LT - Flow Cytometry	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated macrophages in lymphoid tissues (LT) using flow cytometry.	30 months
Secondary	Percent of Activated Dendritic Cells in LT - Flow Cytometry	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the percentage of activated dendritic cells in lymphoid tissues (LT) using flow cytometry.	30 months
Secondary	Intracellular Concentration of IL-17 in PBMCs	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-17 in PBMCs using cytokine staining.	30 months
Secondary	Intracellular Concentration of IFNg in PBMCs	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IFNg in PBMCs using cytokine staining.	30 months
Secondary	Intracellular Concentration of IL-2 in PBMCs	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-2 in PBMCs using cytokine staining.	30 months
Secondary	Intracellular Concentration of TNF in PBMCs	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine TNF in PBMCs using cytokine staining.	30 months
Secondary	Intracellular Concentration of IL-10 in PBMCs	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-10 in PBMCs using cytokine staining.	30 months
Secondary	Intracellular Concentration of GM-CSF in PBMCs	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine GM-CSF in PBMCs using cytokine staining.	30 months
Secondary	Intracellular Concentration of IL-17 in LT	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-17 in lymphoid tissue (LT) using cytokine staining.	30 months
Secondary	Intracellular Concentration of IFNg in LT	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IFNg in lymphoid tissue (LT) using cytokine staining.	30 months
Secondary	Intracellular Concentration of IL-2 in LT	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-2 in lymphoid tissue (LT) using cytokine staining.	30 months
Secondary	Intracellular Concentration of TNF in LT	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine TNF in lymphoid tissue (LT) using cytokine staining.	30 months
Secondary	Intracellular Concentration of IL-10 in LT	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine IL-10 in lymphoid tissue (LT) using cytokine staining.	30 months
Secondary	Intracellular Concentration of GM-CSF in LT	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the intracellular levels of the inflammatory cytokine GM-CSF in lymphoid tissue (LT) using cytokine staining.	30 months
Secondary	Plasma Concentration of LPS	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of LPS by ELISA.	30 months
Secondary	Plasma Concentration of sCD14	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of sCD14 by limulus assay.	30 months
Secondary	Plasma Concentration of I-FABP	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of I-FABP using ELISA.	30 months
Secondary	Plasma Concentration of IL-1b	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-1b using ELISA.	30 months
Secondary	Plasma Concentration of IL-1RA	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-1RA using ELISA.	30 months
Secondary	Plasma Concentration of IL-6	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of IL-6 using ELISA.	30 months
Secondary	Plasma Concentration of TNF	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of TNF using ELISA.	30 months
Secondary	Plasma Concentration of Amyloid A	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of amyloid A using ELISA.	30 months
Secondary	Plasma Concentration of CRP	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of CRP using ELISA.	30 months
Secondary	Plasma Concentration of D-dimer	The Impact of Losartan on Immune Activation in HIV Infected, Treated Individuals will be determined by measuring the plasma concentration of D-dimer using ELISA.	30 months
Secondary	Frequency of HIV RNA+ and DNA+ Cells in LN - Radiolabeled ISH	The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in LN using radiolabeled in situ hybridization (ISH).	30 months
Secondary	Frequency of HIV RNA+ and DNA+ Cells in LN - RNAscopeTM in Situ Technology	The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in LN using RNAscopeTM in situ technology.	30 months
Secondary	Frequency of HIV RNA+ and DNA+ Cells in GALT - Radiolabeled in Situ Hybridization (ISH)	The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in GALT radiolabeled in situ hybridization (ISH).	30 months
Secondary	Frequency of HIV RNA+ and DNA+ Cells in GALT - RNAscopeTM in Situ Technology	The Potential for Losartan to Reduce the Size of the Viral Reservoir will be assessed by determining the frequency of HIV RNA+ and DNA+ cells in GALT using RNAscopeTM in situ technology.	30 months
Secondary	Concentration of Losartan and Antiretrovirals (ARVs)	Potential Drug-drug Interactions Between Losartan and Antiretrovirals (ARVs) will be assessed by measuring levels of ARVs and losartan in plasma and peripheral blood mononuclear cells (PBMCs).	30 months
Secondary	Intracellular Concentration of Losartan and Antiretrovirals (ARVs)	Potential Drug-drug Interactions Between Losartan and Antiretrovirals (ARVs) will be assessed by measuring intracellular concentration of losartan and ARVs in lympoidtissue.	30 months